Metagenomi, Inc. (MGX) - Forward P/S Multiple

Graphic logo of Metagenomi, Inc. (MGX)

Leveraging R&D alliances with pharmaceutical giants, Metagenomi, Inc. (MGX) is developing genetic technologies. Tracking the projected P/S value on GURU.Markets, we note that 3.60 reflects the baseline level of the metric. Patents and stringent FDA oversight create high barriers to entry. Within the business, AI modeling is combined with laboratory robotics, although final patient control remains with the scientists.

MGX metagenomi.co: Market Cap to Projected Revenue in the range 08/16/2024 - 11/16/2026

Analytical breakdowns for Metagenomi, Inc.

- stock price and consensus target price:
Analysis of all company metrics:Metagenomi Inc. MGX
Manufactured products of Metagenomi, Inc.

For Metagenomi, Inc. (MGX), the forward P/S multiple becomes a key tool for assessing market expectations of future revenues amid geopolitical restrictions on the exchange of genetic data. Analyzing this chart, an investor compares current market capitalization with projected sales, which allows for the identification of optimal portfolio rebalancing points while accounting for the risks of slowed drug development due to the disruption of international logistics chains.

Main competitors

Forward P/S Multiple TEM (Tempus Labs)|Qiagen N.V. - Price-to-Projected Revenue Ratio|IONS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio repligen.com|RNA: Forward P/S Multiple|CRISPR Therapeutics Inc (CRSP) - Forward P/S Multiple|WGS (GeneDx Holdings) - Forward P/S Multiple|RARE: Forward Price to Sales|Forward Price-to-Revenue Multiple BEAM (Beam Therapeutics Corp)|SRPT: Future Price to Revenue|Forward P/S Multiple TWST (Twist Bioscience Inc)|Market Cap to Expected Sales Ratio 10x Genomics Corp (TXG)|intelliatx.com - Forward P/S Multiple|Market Cap to Expected Sales Ratio Stoke STOK|biolifesolutions.com (BLFS) - Price-to-Projected Revenue Ratio|WVE - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple MAZE|Forward Price-to-Revenue Multiple Sionna Therapeutics, Inc. (SION)|Forward Price-to-Revenue Multiple PRME (Prime Medicine Bio)|Market Cap to Expected Sales Ratio Taysha|uniQure Pharma - Forward Price-to-Revenue Multiple|MeiraGTx Holdings plc - Price-to-Projected Revenue Ratio|regenxbio.com - Forward P/S Multiple|Solid Bio (SLDB) - Forward Price-to-Revenue Multiple|OCGN: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pacific Biosciences of California|BNTC (Benitec Biopharma Inc.) - Forward P/S Multiple|Market Cap to Projected Revenue DSGN (Design Therapeutics)|Forward P/S Multiple RCKT|Price-to-Projected Revenue Ratio FDMT (4D Molecular Therapeutics Inc)|Forward P/S Multiple LXEO (Lexeo Therapeutics Inc.)|Forward Price to Sales KRRO|EDIT - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Silence Therapeutics SLN|ProQR Therapeutics NV (PRQR) - Price-to-Projected Revenue Ratio|Codexis Inc - Forward Price to Sales|Price-to-Projected Revenue Ratio Sangamo BioSciences|Market Cap to Projected Revenue NAUT (Nautilus Biotechnology)|Price-to-Projected Revenue Ratio Precision BioSciences (DTIL)|GBIO - Market Cap to Future Revenue Ratio|Forward P/S Multiple BOLD (Boundless Bio, Inc)|XCUR - Forward Price-to-Revenue Multiple|IMNN - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Phio Pharmaceuticals Corp|MBIO: Forward P/S Multiple|TransCode (RNAZ) - Forward P/S Multiple|BNGO (Bionano) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Applied DNA Sciences, Inc. APDN|Forward P/S Multiple BLUE|ImmunoPrecise Antibodies Ltd - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Omega Therapeutics OMGA|OMIC: Market Cap to Projected Revenue|RGLS: Forward Price-to-Revenue Multiple|Forward Price to Sales SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Price-to-Projected Revenue Ratio|Future Price to Revenue TCON (TRACON)|Price-to-Projected Revenue Ratio Unity Biotechnology, Inc.